Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials

被引:46
作者
Fitz-Patrick, David [1 ]
Roberson, Kent [2 ]
Niwa, Kiyoshi [3 ]
Fujimura, Takabumi [4 ]
Mori, Koji [5 ]
Hall, Jesse [6 ]
Yan, Xiaohong [6 ]
Shen, Zancong [6 ]
Liu, Sha [6 ]
Ito, Yasushi [6 ]
Baumgartner, Scott [6 ]
机构
[1] East West Med Res Inst, 1585 Kapiolani Blvd, Honolulu, HI 96814 USA
[2] Delta Waves Sleep Disorder & Res Ctr, Colorado Springs, CO USA
[3] Niwa Family Clin, Chofu, Tokyo, Japan
[4] Thinkpk Heart Clin, Tokyo, Japan
[5] Mori Clin, Fukuoka, Fukuoka, Japan
[6] Ardea Biosci Inc, San Diego, CA USA
关键词
Asymptomatic hyperuricemia; gout; selective uric acid reabsorption inhibitor; serum urate; verinurad; EVIDENCE-BASED RECOMMENDATIONS; ACID REABSORPTION INHIBITOR; INADEQUATE RESPONSE; DOUBLE-BLIND; MANAGEMENT; LESINURAD; RISK; ALLOPURINOL; COMBINATION; FEBUXOSTAT;
D O I
10.1080/14397595.2018.1538003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Evaluate efficacy/safety of verinurad monotherapy in patients with gout (Japan/US) or asymptomatic hyperuricemia (Japan). Methods: Two randomized, placebo-controlled, phase II studies were conducted (NCT01927198/NCT02078219). Patients were randomized to once-daily doses of placebo or escalating doses of verinurad (study 1: 5-12.5mg; study 2: 2.5-15mg). Primary endpoint was percentage change from baseline in serum urate (sUA) at week 12 (study 1)/week 16 (study 2). Safety was also assessed. Results: Most patients in study 1 (n=171) were white (74.9%); all patients were Japanese in study 2 (n=204). Least squares means (SE) estimate of percentage change in sUA levels from baseline in study 1 was 1.2 +/- 2.9 for placebo, and -17.5 +/- 2.8, -29.1 +/- 2.8, -34.4 +/- 2.9 for verinurad 5, 10, 12.5mg, respectively. In study 2, results were -2.4 +/- 2.5 and -31.7 +/- 2.5, -51.7 +/- 2.6,-55.8 +/- 2.5, respectively. Difference from placebo was significant for each verinurad dose (p<.0001). The proportion of patients with treatment-emergent adverse events (TEAEs) was similar across all groups. Renal-related TEAEs were more common with verinurad than placebo. Conclusion: Verinurad monotherapy resulted in sustained reductions in sUA in Japanese/US patients but renal AEs occurred, so verinurad alone is not recommended for treatment of hyperuricemia or gout. The renal consequences of excessive uric acid excretion deserve study.
引用
收藏
页码:1042 / 1052
页数:11
相关论文
共 27 条
[1]   Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) [J].
Bardin, Thomas ;
Keenan, Robert T. ;
Khanna, Puja P. ;
Kopicko, Jeff ;
Fung, Maple ;
Bhakta, Nihar ;
Adler, Scott ;
Storgard, Chris ;
Baumgartner, Scott ;
So, Alexander .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (05) :811-820
[2]   Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout Findings of a Phase III Clinical Trial [J].
Dalbeth, Nicola ;
Jones, Graeme ;
Terkeltaub, Robert ;
Khanna, Dinesh ;
Kopicko, Jeff ;
Bhakta, Nihar ;
Adler, Scott ;
Fung, Maple ;
Storgard, Chris ;
Baumgartner, Scott ;
Perez-Ruiz, Fernando .
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (09) :1903-1913
[3]  
DiBonaventura MD, 2012, EXPERT REV PHARM OUT, V12, P821, DOI [10.1586/ERP.12.60, 10.1586/erp.12.60]
[4]   Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study [J].
Fleischmann, Roy ;
Winkle, Peter ;
Miner, Jeffrey N. ;
Yan, Xiaohong ;
Hicks, Liz ;
Valdez, Shakti ;
Hall, Jesse ;
Liu, Sha ;
Shen, Zancong ;
Gillen, Michael ;
Hernandez-Illas, Martha .
RMD OPEN, 2018, 4 (01)
[5]   Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects [J].
Hall, Jesse ;
Gillen, Michael ;
Liu, Sha ;
Miner, Jeffrey N. ;
Valdez, Shakti ;
Shen, Zancong ;
Lee, Caroline .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :1799-1807
[6]   2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia [J].
Khanna, Dinesh ;
Fitzgerald, John D. ;
Khanna, Puja P. ;
Bae, Sangmee ;
Singh, Manjit K. ;
Neogi, Tuhina ;
Pillinger, Michael H. ;
Merill, Joan ;
Lee, Susan ;
Prakash, Shraddha ;
Kaldas, Marian ;
Gogia, Maneesh ;
Perez-Ruiz, Fernando ;
Taylor, Will ;
Liote, Frederic ;
Choi, Hyon ;
Singh, Jasvinder A. ;
Dalbeth, Nicola ;
Kaplan, Sanford ;
Niyyar, Vandana ;
Jones, Danielle ;
Yarows, Steven A. ;
Roessler, Blake ;
Kerr, Gail ;
King, Charles ;
Levy, Gerald ;
Furst, Daniel E. ;
Edwards, N. Lawrence ;
Mandell, Brian ;
Schumacher, H. Ralph ;
Robbins, Mark ;
Wenger, Neil ;
Terkeltaub, Robert .
ARTHRITIS CARE & RESEARCH, 2012, 64 (10) :1431-1446
[7]   A benefit-risk assessment of benzbromarone in the treatment of gout - Was its withdrawal from the market in the best interest of patients? [J].
Lee, Ming-Han H. ;
Graham, Garry G. ;
Williams, Kenneth M. ;
Day, Richard O. .
DRUG SAFETY, 2008, 31 (08) :643-665
[8]   Gout treatment: should we aim for rapid crystal dissolution? [J].
Pascual, Eliseo ;
Andres, Mariano ;
Vela, Paloma .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (05) :635-637
[9]   Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout [J].
Perez-Ruiz, F ;
Calabozo, M ;
Pijoan, J ;
Herrero-Beites, AM ;
Ruibal, A .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (04) :356-360
[10]   Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol [J].
Perez-Ruiz, Fernando ;
Sundy, John S. ;
Miner, Jeffrey N. ;
Cravets, Matthew ;
Storgard, Chris .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) :1074-1080